Integra LifeSciences (NASDAQ:IART) Updates Q1 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.400-0.450 for the period, compared to the consensus EPS estimate of 0.560. The company issued revenue guidance of $375.0 million-$385.0 million, compared to the consensus revenue estimate of $411.7 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Analyst Upgrades and Downgrades

IART has been the topic of a number of analyst reports. Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley began coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target for the company. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART traded up $2.31 during mid-day trading on Tuesday, hitting $24.36. The company had a trading volume of 202,650 shares, compared to its average volume of 551,138. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $44.91. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The firm’s 50 day simple moving average is $23.68 and its two-hundred day simple moving average is $21.81. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -269.58, a PEG ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.86 by $0.11. The business had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.89 earnings per share. As a group, equities research analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.10% of the stock is owned by company insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.